临床试验登记· Heidelberg University · ClinicalTrials.gov·· 3 小时前评分24
iVOCAL 1 期试验评估 IDH1R132H 肽疫苗联合 vorasidenib 治疗复发 IDH1R132H 突变星形细胞瘤（WHO 2-4 级）
A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)
导读
Heidelberg University 计划开展 iVOCAL 1 期多中心试验，评估 IDH1R132H 肽疫苗（IDH1-vac）联合 IDH1/2 抑制剂 vorasidenib 治疗复发 IDH1R132H 突变星形细胞瘤（WHO 2-4 级）。
来源：临床试验登记 · clinicaltrials.gov